Role of biomarkers in progression of chronic cerebral ischemia

Abstract

The purpose of investigation is to study role of biomarkers in progression of chronic cerebral ischemia (CCI). Material and methods: It was examined 355 patients with CCI (main group). Among of them there were 230 women and 125 men. Average age was 55.30 ± 7.91 years. Control group consisted of 50 clinically healthy people (28 women and 22 men) without any signs of cerebrovascular diseases (CVD). Average of age 52.30 ± 8.51 years. Clinical-neuropsychological, laboratory and instrumental methods of examination were used in the given work. For the determination of CCI progression factors it was applied a logistic regression analysis. Results. Presence of leukoaraiosis areas, postischemic cysts, combined focal lesion of white substance and dilation of subarachnoid spaces or/and ventricular system of brain, S100 protein, presence of atherosclerotic plaques in common carotids, age, bodymass index, type 2 diabetes mellitus, dyslipidemia, cholesterol of low density lipoproteins, systolic blood pressure, antibodies to NR2 peptide, male sex and homocysteine of blood are independent predictors of DE progression. Corrected ROC-analysis showed that using as a standard prognostic model (Model 1) a combined index of white substance focal lesion, dilation of subarachnoid spaces or/and ventricular system of brain a magnitude AUC = 0,612 that indicates about sufficiently high system reliability. At that, a combined usage of three biomarkers (homocysteine + S100 protein + antibodies to NR2) significantly increases a prognostic value of Model 1 (p=0,002). Conclusions: Combined usage of studied biomarkers such as homocysteine, S100B protein and antibodies to NR2-peptide in blood plasma together with dete-96 Alina Viktorivna Demchenko ction of traditional risk factors of CVD significantly increase a factor of an early diagnostics and a prognostic significance of CCI progression.